Toxicity & side effects: switching therapy

Lisa A. Spacek, M.D., Ph.D.
Toxicity & side effects: switching therapy is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

DEFINITION

  • Modification of ART regimen in virologically suppressed patients[3]
    • Reduce or prevent toxicity
      • Newer regimens are associated with fewer serious adverse effects. From 2011 to 2017, Swedish registry found that reporting of side effects decreased from 32% to 15%.[8]
      • PLWH initiating ART in trials report short-term adverse effects infrequently (< 10%).
    • Improve long-term adherence by reducing pill burden and dosing frequency OR eliminating dietary requirements[2]
    • Avoid long-term ART toxicities, especially in setting of co-morbidities, such as cardiovascular, kidney, or metabolic disease
    • Avoid drug interactions
      • For example, in solid organ transplantation, drug-drug interactions occur between protease inhibitors (i.e., DRV) or pharmacokinetic boosters (i.e., cobi) and required immunosuppressive medications (i.e., tacrolimus).[2]
    • Exercise option of long-acting injectable ART

-- To view the remaining sections of this topic, please or --

DEFINITION

  • Modification of ART regimen in virologically suppressed patients[3]
    • Reduce or prevent toxicity
      • Newer regimens are associated with fewer serious adverse effects. From 2011 to 2017, Swedish registry found that reporting of side effects decreased from 32% to 15%.[8]
      • PLWH initiating ART in trials report short-term adverse effects infrequently (< 10%).
    • Improve long-term adherence by reducing pill burden and dosing frequency OR eliminating dietary requirements[2]
    • Avoid long-term ART toxicities, especially in setting of co-morbidities, such as cardiovascular, kidney, or metabolic disease
    • Avoid drug interactions
      • For example, in solid organ transplantation, drug-drug interactions occur between protease inhibitors (i.e., DRV) or pharmacokinetic boosters (i.e., cobi) and required immunosuppressive medications (i.e., tacrolimus).[2]
    • Exercise option of long-acting injectable ART

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2022